产品说明书

Dehydroevodiamine

Print
Chemical Structure| 67909-49-3 同义名 : DHED
CAS号 : 67909-49-3
货号 : A787273
分子式 : C19H15N3O
纯度 : 99%+
分子量 : 301.342
MDL号 : MFCD11656140
存储条件：

粉末 Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 7 mg/mL(23.23 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
描述 Dehydroevodiamine (DHED) is a major bioactive quinazoline alkaloid isolated from Evodiae Fructus, and has an antiarrhythmic effect in guinea-pig ventricular myocytes[3]. Dehydroevodiamine (0-50 μM; 2 hours) inhibits iNOS and COX-2 expression and prevents degradation of IκB-α in LPS induced RAW 264.7 macrophages[4]. Similarly to the cholinesterase inhibitor, physostigmine (0.03--0.3 mg/kg, i.p.), dehydroevodiamine (0.75--12.0 mg/kg, i.p.) administered 30 min before the training trial, immediately after the training trial, and 30 min before the retention test significantly improved scopolamine- and beta-amyloid peptide-(25--35)-induced amnesia[5]. DHED (10 mg/kg, p.o.) and Donepezil (1 mg/kg, p.o.) ameliorated the spatial memory impairment in the scopolamine-induced amnestic rats[6]. DHED could suppress the overactivation of GSK-3 (glycogen synthase kinase-3) and improve tau hyperphosphorylation and spatial memory deficit of the rats[7]. DHED (Pre-incubation of the brain slices with DHED) can attenuate CA(calyculin A)-induced tau hyperphosphorylation at multiple AD-related sites in metabolically active rat brain slices[8].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.32mL

0.66mL

0.33mL

16.59mL

3.32mL

1.66mL

33.18mL

6.64mL

3.32mL
参考文献

[1]Shin KY, Kim KY, Suh YH. Dehydroevodiamine·HCl enhances cognitive function in memory-impaired rat models. Korean J Physiol Pharmacol. 2017 Jan;21(1):55-64.

[2]Shin KY, Noh SJ, et al. Dehydroevodiamine•HCl Protects Against Memory Impairment and Cerebral Amyloid-β Production in Tg2576 Mice by Acting as a γ-Secretase Inhibitor. CNS Neurol Disord Drug Targets. 2016;15(8):935-944.

[3]Loh SH, Tsai YT, Lee CY, Chang CY, Tsai CS, Cheng TH, Lin CI. Antiarrhythmic effects of dehydroevodiamine in isolated human myocardium and cardiomyocytes. J Ethnopharmacol. 2014 May 14;153(3):753-62

[4]Noh EJ, Ahn KS, Shin EM, Jung SH, Kim YS. Inhibition of lipopolysaccharide-induced iNOS and COX-2 expression by dehydroevodiamine through suppression of NF-kappaB activation in RAW 264.7 macrophages. Life Sci. 2006 Jul 10;79(7):695-701

[5]Wang HH, Chou CJ, Liao JF, Chen CF. Dehydroevodiamine attenuates beta-amyloid peptide-induced amnesia in mice. Eur J Pharmacol. 2001 Feb 16;413(2-3):221-5

[6]Shin KY, Kim KY, Suh YH. Dehydroevodiamine•HCl enhances cognitive function in memory-impaired rat models. Korean J Physiol Pharmacol. 2017 Jan;21(1):55-64

[7]Peng JH, Zhang CE, Wei W, Hong XP, Pan XP, Wang JZ. Dehydroevodiamine attenuates tau hyperphosphorylation and spatial memory deficit induced by activation of glycogen synthase kinase-3 in rats. Neuropharmacology. 2007 Jun;52(7):1521-7

[8]Fang J, Liu R, Tian Q, Hong XP, Wang SH, Cao FY, Pan XP, Wang JZ. Dehydroevodiamine attenuates calyculin A-induced tau hyperphosphorylation in rat brain slices. Acta Pharmacol Sin. 2007 Nov;28(11):1717-23